市场调查报告书
商品编码
1452978
全球生命科学分析软体市场 2024-2031Global Life Science Analytics Software Market 2024-2031 |
预计全球生命科学分析软体市场在预测期内(2024-2031 年)CAGR将达到 13.3%。分析软体在临床试验和设计应用中的日益采用是支持全球市场成长的关键因素。市场参与者正在使用分析软体,透过促进更定量、可靠和协作的临床试验设计方法来加速新药的发现。市场参与者也专注于引入生命科学分析软体解决方案,以进一步促进市场成长。例如,2023 年 2 月,生命科学领域的统计软体和高级分析供应商 Cytel Inc. 与 GSK 合作部署了临床策略平台 Solara。透过使用该平台,葛兰素史克能够有效协调试验目标,管理试验不确定性,并创建经过压力测试的临床试验设计,从而节省成本和时间。该软体的高成本会限制其市场成长。
全球生命科学分析软体市场按组件、交付模型和应用程式进行细分。根据组件,市场分为服务和软体。根据交付模式,市场分为本地模式和按需模式。此外,根据应用,市场分为研发、临床试验、销售和行销、供应链优化、药物警戒和其他(监管合规)。在这些组件中,由于在药物发现和验证、实验室管理、运行临床试验和创建新医疗设备方面的应用不断增加,预计软体细分市场将占据相当大的市场份额。
在这些应用中,临床试验细分市场预计将在全球生命科学分析软体市场中占据相当大的份额。这一细分市场的成长归因于临床试验中越来越多地采用生命科学分析解决方案,包括病理检测和创建可行的治疗方案,拓宽了患者选择的界限,快速对不同方面进行分类,并协助研究人员更准确地识别患有以下疾病的个体:符合纳入和排除标准。各种平台提供人工智慧和机器学习增强的软体解决方案,以自动化关键的临床开发程序,并在一个地方提供试验操作和患者进展的深入概述。例如,2023 年 6 月,Saama 推出了人工智慧驱动的资料平台,以加速临床开发。基于 SaaS 的产品的统一平台与其现有的客製化解决方案和服务组合相配合。
全球生命科学分析软体市场根据地理位置进一步细分,包括北美(美国和加拿大)、欧洲(英国、义大利、西班牙、德国、法国和欧洲其他地区)、亚太地区(印度、中国) 、日本、韩国和亚洲其他地区),以及世界其他地区(中东和非洲以及拉丁美洲。其中,亚太地区预计将在全球市场中呈现最高的CAGR。投资不断增加在医疗保健IT领域,医疗保健基础设施的建设、主要竞争对手的出现以及临床试验投资的增加是区域市场成长的关键因素。
在所有地区中,北美地区占据全球市场的主要份额。区域份额归因于越来越多地采用分析解决方案来处理大量复杂资料并产生深入的见解,从而改善精准医学和临床试验的整体解决方案,推动市场的成长。医疗保健公司提供分析解决方案,用于在整个治疗的各个阶段发展患者的观点。使用统一资料并具有一套全面的分析和机器学习功能的单一平台。例如,2022 年 3 月,Databricks 为医疗保健和生命科学产业的组织推出了产业 Lakehouse 平台。借助用于资料管理、分析和疾病预测、医学影像分类和生物标记发现等先进人工智慧用例的单一平台,医疗保健组织可以兑现精准医疗的承诺。
服务生命科学分析软体市场的主要公司包括 Cognizant Technology Solutions Corp.、IQVIA Inc.、Microsoft Corp.、Oracle Corp.、Salesforce, Inc. 等。市场参与者透过各种策略(包括併购、合作、合作、融资和新产品发布),为市场成长做出了巨大贡献,以保持市场竞争力。例如,2022 年 1 月,Francisco 收购了 IBM 公司广泛的分析产品和资料集,例如临床开发、影像软体、社会专案管理、健康洞察和 Micromedex。
Global Life Science Analytics Software Market Size, Share & Trends Analysis Report by Component (Services and Software), by Delivery Model (On-Premise Model and On-Demand Model), and by Application (Research & Development, Clinical Trials, Sales & Marketing, Supply Chain Optimization, Pharmacovigilance, and Others), Forecast Period (2024-2031)
The global life science analytics software market is anticipated to grow at a significant CAGR of 13.3% during the forecast period (2024-2031). The growing adoption of analytics software in clinical trial and design applications is the key factor supporting the growth of the market globally. Analytical software is being used by market players to speed up the discovery of new medications by facilitating a more quantitative, reliable, and collaborative approach to clinical trial design. The market players are also focusing on introducing life science analytics software solutions that further bolster the market growth. For instance, in February 2023, Cytel Inc., a statistical software and advanced analytics provider in life sciences partnered with GSK to deploy the clinical strategy platform Solara. With the use of the platform, GSK is able to effectively coordinate trial objectives, manage trial uncertainties, and create pressure-tested clinical trial designs that save costs and time. The high cost of this software can restrain their market growth.
The global life science analytics software market is segmented on the component, delivery model, and application. Based on the component, the market is sub-segmented into services and software. Based on the delivery model, the market is sub-segmented into the on-premise model and on-demand model. Further, based on application, the market is sub-segmented in research & development, clinical trials, sales & marketing, supply chain optimization, pharmacovigilance, and others (regulatory compliance). Among the components, the software sub-segment is anticipated to hold a considerable share of the market owing to the increasing application in drug discovery and validation, laboratory administration, running clinical trials, and creating new medical devices.
Among the applications, the clinical trials sub-segment is expected to hold a considerable share of the global life science analytics software market. The segmental growth is attributed to the increasing adoption of life science analytics solutions in clinical trials that include pathology detection and the creation of viable treatment options broadening the boundaries for patient selection, quickly sorting through different aspects, and assisting researchers in more precisely identifying individuals who meet inclusion and exclusion criteria. Various Platforms offer AI and ML-enhanced software solutions to automate critical clinical development procedures and offer an in-depth overview of trial operations and patient progress in one place. For instance, in June 2023, Saama introduced an AI-driven data platform to accelerate clinical development. The unified platform of SaaS-based products to accompany its existing portfolio of customized solutions and services.
The global life science analytics software market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to exhibit the highest CAGR in the global market. The increasing investments in healthcare IT, building healthcare infrastructure, the emergence of major competitors, and rising investment in clinical trials are key contributing factors to the regional market growth.
Among all regions, the North American region holds the major share of the global market. Regional share is attributed to the increasing adoption of analytics solutions to process large volumes of complex data and produce in-depth insights, thereby improving the overall solution for precision medicine and clinical trials driving the growth of the market. Healthcare companies provide analytics solutions for developing patient perspectives throughout all stages of treatment. Using a single platform that unifies data and has a comprehensive set of analytics and machine learning features. For instance, in March 2022, Databricks launched the industry's lakehouse platform for organizations across the healthcare and life sciences industries. With a single platform for data management, analytics, and advanced AI use cases like disease prediction, medical image classification, and biomarker discovery, healthcare organizations can deliver on the promise of precision medicine.
The major companies serving the life science analytics software market include Cognizant Technology Solutions Corp., IQVIA Inc., Microsoft Corp., Oracle Corp., Salesforce, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Francisco acquired IBM Corp.'s wide range of analytic products and data sets, such as clinical development, imaging software, social program management, health insights, and Micromedex.